- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)
Daunorubicin with cytarabine – July 2023
Daunorubicin with cytarabine: Powder for I.V. infusion containing daunorubicin 44 mg and cytarabine 100 mg; Vyxeos® - July 2023
Last updated
10 November 2023